Clinical Trials Browser

Has results × axicabtagene ciloleucel × Clear all

Lymphoma, Mantle-Cell

NCT03642626 2026-01-23

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Phase 2 Active not recruiting

150 enrolled 23 charts

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03105336 2025-12-23

ZUMA-5

Phase 2 Completed

159 enrolled 27 charts 1 FDA

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03391466 2025-12-01

ZUMA-7

Phase 3 Completed

359 enrolled 27 charts 1 FDA

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Phase 2 Completed

15 enrolled 17 charts

Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

NCT05108805 2025-03-27

Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

Phase 4 Completed

25 enrolled 17 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04432506 2025-01-28

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

Phase 2 Completed

22 enrolled 15 charts

LymphoidOther hematologic neoplasm

Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

NCT03761056 2024-12-04

ZUMA-12

Phase 2 Completed

42 enrolled 20 charts

Lymphoid

Lymphoma, B-Cell

NCT02926833 2024-03-06

ZUMA-6

Phase 1/2 Completed

37 enrolled 28 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

Clinical Trials

ZUMA-2

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

ZUMA-5

ZUMA-7

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

ZUMA-12

ZUMA-6